Bristol-Myers Squibb Reports Third Quarter Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rebounds, but yield surge sets stage for weekly losses
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Leerink Partners Remains Bullish After Opdivo and HCV Help Drive 3Q Beat for Bristol-Myers Squibb (BMY)
October 28, 2015 8:20 AM EDTLeerink Partners reiterated an Outperform rating and $77.00 Price Target on Bristol-Myers Squibb Co. (NYSE: BMY) following 3Q earnings results. Non-GAAP EPS of $0.39 beat the Street estimates of $0.35. Global revenue was $4.1B, above consensus $3.9B expectations.
Analyst Seamus Fernandez commented, "BMY reported strong 3Q:15... More
Bristol-Myers Squibb (BMY) Tops Q3 EPS by 4c; Boosts FY15 EPS Outlook
October 27, 2015 6:59 AM EDTBristol-Myers Squibb (NYSE: BMY) reported Q3 EPS of $0.39, $0.04 better than the analyst estimate of $0.35. Revenue for the quarter came in at $4.07 billion versus the consensus estimate of $3.83 billion.
Guidance:
Bristol-Myers Squibb sees FY2015 EPS of $1.85-$1.90, versus the consensus of... More
